Opioid Use Disorder (OUD) Treatment and Harm Reduction Training Using AR (Augmented Reality) Technology

使用 AR（增强现实）技术进行阿片类药物使用障碍 (OUD) 治疗和减害培训

• 批准号: 10428673
• 负责人: DOUGLAS NELSON
• 金额: $ 94.84万
• 依托单位: LUMIS CORP.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-15 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10428673
• 关键词: Accident and Emergency department; Adoption; Attitude; Augmented Reality; Basic Life Support; Benchmarking; COVID-19 pandemic; Cardiopulmonary Resuscitation; Caregivers; Cellular Phone; Cessation of life; Clinic; Clinical; Collaborations; Communities; Complex; Computer software; Credentialing; Data; Development; Devices; Disease; Drug usage; Drug user; Ecosystem; Education; Educational Curriculum; Effectiveness; Emergency Medical Technicians; Epidemic; Equipment; Family member; Feasibility Studies; Feedback; Florida; Focus Groups; Goals; Harm Reduction; Health; Health Personnel; Health Professional; Healthcare; Hospital Departments; Immersion; Knowledge; Manikins; Marketing; Maryland; Measures; Medicine; Mission; Modality; Naloxone; National Institute of Drug Abuse; New Hampshire; Nursing Schools; Ohio; Opioid; Overdose; Paramedical Personnel; Participant; Patients; Pennsylvania; Peripheral; Persons; Pharmaceutical Preparations; Pharmacotherapy; Pharmacy facility; Phase; Process; Professional Organizations; Provider; Recommendation; Reporting; Research; Research Design; Research Methodology; Resources; Site; Small Business Innovation Research Grant; Substance Use Disorder; System; Tablets; Technology; Testing; Time; Training; Training Support; Treatment outcome; United States; Universities; West Virginia; base; college; commercialization; cost; design; effectiveness validation; efficacy evaluation; efficacy validation; experience; implementation protocol; improved; improved outcome; insight; instrument; knowledge base; medical schools; operation; opioid overdose; opioid use disorder; overdose death; overdose education; pilot test; prescription opioid; programs; prototype; recruit; response; simulation; success; synthetic opioid; treatment services; usability; virtual experiments

Over the last decade, drug overdose death has created an epidemic across the United States. In 2018, there were 67,367 drug overdose deaths—a decrease of about 4.6% from 2017—but almost 70% of the deaths involved opioids. While overdoses related to prescription opioids have decreased, synthetic opioids made up over two-thirds of all opioid-related overdose deaths in 2018. West Virginia, Maryland, Pennsylvania, Ohio, and New Hampshire had the highest rates of drug overdose deaths in 2018. Furthermore, there are reported increases in overdose deaths that may result from isolation and access to drugs and treatment services related to the COVID-19 pandemic. The goal of this proposal is closely aligned with the mission of the National Institute on Drug Abuse (NIDA) to educate clinical providers and lay people on improving treatment and outcomes for those suffering from substance use disorders (SUDs), specifically in response to drug overdose. Many barriers have been identified for training providers on SUDs. Simulation-based training has shown promise for training providers about responding to drug overdose during Basic Life Support (BLS) training. However, simulation-based training is usually resource intensive and can be difficult to implement as current simulator technologies require facilities, staff, and technology support. Overdose education and naloxone distribution (OEND) is associated with improved outcomes for people experiencing opioid overdose as well as decreased drug use by people who participated in OEND programs. Increasing access to OEND could expand these positive results. This Phase II SBIR aims to further develop Lumis’s Augmented Reality Training on Overdose (ART-OD) within Lumis’s existing healthcare training simulator, the InSight Platform. The InSight Platform incorporates knowledge-based and hands-on training, requires less resources than traditional simulation, and supports broad deployment. The ART-OD prototype developed in Phase I met all benchmarks for success, including: (1) development and integration of an ART-OD prototype into the InSight Platform, (2) increased knowledge and attitudes towards recognizing and responding to an opioid overdose, and (3) positive feedback, usability, and market acceptance from various stakeholders. Mixed methods research will: (1) enhance the design of ART-OD developed in Phase I using an expanded pool of subject matter experts (SMEs) and integration with an existing prototype for training clinicians from the University of Florida College of Medicine (UCF COM), (2) integrating the enhanced design for ART-OD and the UCF COM prototype into an advanced ART-OD product, and (3) conducting pilot testing of ART-OD with potential end-users and stakeholders to validate training effectiveness and market potential.

过去十年，药物过量死亡已在美国蔓延，2018 年， 共有 67,367 人因药物过量死亡，比 2017 年下降了约 4.6%，但死亡人数中几乎有 70% 虽然与处方阿片类药物相关的过量用药有所减少，但合成阿片类药物有所增加。 2018 年，超过三分之二的阿片类药物过量死亡病例。西弗吉尼亚州、马里兰州、宾夕法尼亚州、俄亥俄州和 新罕布什尔州 2018 年药物过量死亡率最高。此外，有报道称 因隔离以及获得相关药物和治疗服务而导致的服药过量死亡人数增加 该提案的目标与国家研究所的使命密切相关。 药物滥用 (NIDA) 旨在教育临床提供者和普通民众改善药物滥用的治疗和结果 那些患有物质使用障碍 (SUD) 的人，特别是因药物过量而出现的情况。 事实证明，基于模拟的培训给培训提供者带来了许多障碍。 向培训提供者承诺在基本生命支持 (BLS) 培训期间应对药物过量。 然而，基于模拟的培训通常是资源密集型的，并且根据当前的情况可能难以实施 模拟器技术需要设施、人员和技术支持。 过量用药教育和纳洛酮分配 (OEND) 与改善人们的预后相关 参与 OEND 计划的人服用阿片类药物过量以及减少药物使用。 增加对 OEND 的访问可以扩大这些积极成果。 第二阶段 SBIR 旨在进一步开发 Lumis 的过量用药增强现实培训 (ART-OD) InSight 平台包含在 Lumis 现有的医疗保健培训模拟器中。 基于知识和实践的培训，比传统模拟需要更少的资源，并支持广泛的 第一阶段开发的 ART-OD 原型满足了所有成功基准，包括：(1) 开发 ART-OD 原型并将其集成到 InSight 平台中，(2) 增加知识和 对识别和应对阿片类药物过量的态度，以及 (3) 积极反馈、可用性和 得到各利益相关方的市场认可。 混合方法研究将：（1）使用 扩大主题专家（SME）库并与培训人群的现有原型集成 来自佛罗里达大学医学院 (UCF COM)，(2) 集成 ART-OD 的增强设计 并将 UCF COM 原型转化为先进的 ART-OD 产品，以及 (3) 对 ART-OD 进行试点测试 潜在的最终用户和利益相关者验证培训效果和市场潜力。